The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals

被引:292
|
作者
Hitotsumatsu, Osamu [1 ]
Ahmad, Regina-Celeste [1 ]
Tavares, Rita [1 ]
Wang, Min [1 ]
Philpott, Dana [2 ]
Turer, Emre E. [1 ]
Lee, Bettina L. [1 ]
Shiffin, Nataliya [1 ]
Advincula, Rommel [1 ]
Malynn, Barbara A. [1 ]
Werts, Catherine [2 ]
Ma, Averil [1 ]
机构
[1] Univ Calif San Francisco, Dept Med, Div Gastroenterol, Program Biomed Sci,UCSF Colitis Ctr, San Francisco, CA 94143 USA
[2] Inst Pasteur, Grp Immunite Innee Signalisat, Paris, France
关键词
D O I
10.1016/j.immuni.2008.02.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Muramyl dipeptide (MDP), a product of bacterial cell-wall peptidoglycan, activates innate immune cells by stimulating nucleotide-binding oligomerization domain containing 2 (NOD2) -dependent activation of the transcription factor NF kappa B and transcription of proinflammatory genes. A20 is a ubiquitin-modifying enzyme that restricts tumor necrosis factor (TNF) receptor and Toll-like receptor (TLR) -induced signals. We now show that MDP induces ubiquitylation of receptor-interacting protein 2 (RIP2) in primary macrophages. A20-deficient cells exhibit dramatically amplified responses to MDP, including increased RIP2 ubiquitylation, prolonged NF kappa B signaling, and increased production of proinflammatory cytokines. In addition, in vivo responses to MDP are exaggerated in A20-deficient mice and in chimeric mice bearing A20-deficient hematopoietic cells. These exaggerated responses occur independently of the TLR adaptors MyD88 and TRIF as well as TNF signals. These findings indicate that A20 directly restricts NOD2 induced signals in vitro and in vivo, and provide new insights into how these signals are physiologically restricted.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 50 条
  • [1] Advances in the Study of the Ubiquitin-Editing Enzyme A20
    Bai, Wenya
    Huo, Siying
    Li, Junjie
    Shao, Jianlin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Ubiquitin-Editing Enzyme A20 Restricts TCR-Induced T Cell Activation
    Oshima, Shigeru
    Ma, Averil
    Watanabe, Mamoru
    DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (11) : 2728 - 2729
  • [3] The Ubiquitin-Editing Enzyme A20 Restricts TCR Induced NFkB and T Cell Activation
    Oshima, Shigeru
    Tavares, Rita M.
    Turer, Emre
    Ahmad, Regina-Celeste
    Ma, Averil I.
    GASTROENTEROLOGY, 2009, 136 (05) : A408 - A408
  • [4] The ubiquitin-editing enzyme A20 in a murine model of the demyelination
    Montarolo, F.
    Perga, S.
    Parolisi, R.
    Vitacolonna, A.
    Martire, S.
    Boda, E.
    Buffo, A.
    Bertolotto, A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 208 - 208
  • [5] The ubiquitin-editing enzyme A20 regulates synapse remodeling and efficacy
    Mei, Shaolin
    Ruan, Hongyu
    Ma, Qi
    Yao, Wei-Dong
    BRAIN RESEARCH, 2020, 1727
  • [6] A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme
    Malynn, Barbara A.
    Ma, Averil
    JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (05): : 977 - 980
  • [7] Ubiquitin-Editing Enzyme A20 Promotes Tolerance to Lipopolysaccharide in Enterocytes
    Wang, Jin
    Ouyang, Yannan
    Guner, Yigit
    Ford, Henri R.
    Grishin, Anatoly V.
    JOURNAL OF IMMUNOLOGY, 2009, 183 (02): : 1384 - 1392
  • [8] The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology
    Vereecke, Lars
    Beyaert, Rudi
    van Loo, Geert
    TRENDS IN IMMUNOLOGY, 2009, 30 (08) : 383 - 391
  • [9] The ubiquitin-editing enzyme A20 is required for limiting NOD2 dependent NFkB signaling
    Hitotsumatsu, Osamu
    Ahmad, Regina-Celeste
    Werts, Catherine
    Turer, Emre
    Shifrin, Nataliya
    Lee, Bettina
    Philpott, Dana J.
    Ma, Averil
    GASTROENTEROLOGY, 2007, 132 (04) : A32 - A32
  • [10] Nucleotide-binding oligomerization domain containing 2: Structure, function, and diseases
    Yao, Qingping
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2013, 43 (01) : 125 - 130